company background image
ORNBV logo

Orion Oyj HLSE:ORNBV Stock Report

Last Price

€45.10

Market Cap

€6.3b

7D

1.1%

1Y

22.4%

Updated

04 Nov, 2024

Data

Company Financials +

ORNBV Stock Overview

Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.

ORNBV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance6/6
Financial Health5/6
Dividends4/6

Orion Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orion Oyj
Historical stock prices
Current Share Price€45.10
52 Week High€50.16
52 Week Low€31.86
Beta0.35
11 Month Change-5.59%
3 Month Change5.57%
1 Year Change22.39%
33 Year Change16.87%
5 Year Change12.86%
Change since IPO224.46%

Recent News & Updates

Recent updates

Orion Oyj's (HEL:ORNBV) Shareholders Might Be Looking For Exit

Sep 25
Orion Oyj's (HEL:ORNBV) Shareholders Might Be Looking For Exit

Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Sep 02
Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Orion Oyj Just Beat EPS By 13%: Here's What Analysts Think Will Happen Next

Aug 12
Orion Oyj Just Beat EPS By 13%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 42%?

Jul 14
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 42%?

Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon

Jun 17
Orion Oyj's (HEL:ORNBV) Shares May Have Run Too Fast Too Soon

Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly

May 27
Here's Why Orion Oyj (HEL:ORNBV) Can Manage Its Debt Responsibly

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

May 05
We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Orion Oyj Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Apr 27
Orion Oyj Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 16
Earnings Beat: Orion Oyj Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Why Investors Shouldn't Be Surprised By Orion Oyj's (HEL:ORNBV) P/E

Feb 01
Why Investors Shouldn't Be Surprised By Orion Oyj's (HEL:ORNBV) P/E

Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Jan 11
Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

Nov 28
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Nov 03
We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Oct 05
Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price

Aug 18
Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Jun 21
Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

May 16
A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching

Apr 07
Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Mar 20
Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's

Feb 12
Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Feb 07
A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?

Oct 13
Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?

Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly

Sep 22
Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly

This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year

Jul 21
This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year

Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?

Jul 10
Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?

Shareholder Returns

ORNBVFI PharmaceuticalsFI Market
7D1.1%-2.8%-2.5%
1Y22.4%10.7%3.0%

Return vs Industry: ORNBV exceeded the Finnish Pharmaceuticals industry which returned 11.6% over the past year.

Return vs Market: ORNBV exceeded the Finnish Market which returned 3.2% over the past year.

Price Volatility

Is ORNBV's price volatile compared to industry and market?
ORNBV volatility
ORNBV Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement4.0%
10% most volatile stocks in FI Market6.7%
10% least volatile stocks in FI Market2.6%

Stable Share Price: ORNBV has not had significant price volatility in the past 3 months compared to the Finnish market.

Volatility Over Time: ORNBV's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19173,867Liisa Hurmewww.orion.fi

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Orion Oyj Fundamentals Summary

How do Orion Oyj's earnings and revenue compare to its market cap?
ORNBV fundamental statistics
Market cap€6.33b
Earnings (TTM)€331.70m
Revenue (TTM)€1.43b

19.1x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORNBV income statement (TTM)
Revenue€1.43b
Cost of Revenue€573.20m
Gross Profit€856.00m
Other Expenses€524.30m
Earnings€331.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 25, 2025

Earnings per share (EPS)2.36
Gross Margin59.89%
Net Profit Margin23.21%
Debt/Equity Ratio27.8%

How did ORNBV perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

69%

Payout Ratio